Yoshikazu ISHII 1929 1980 1980 1983 Knothe 1 1 DN SHV- ESBL CTX-M- B C D 4 2 B 3 B D C ESBL 3 ESBL TEM- SHV- 1 Kluyvera CTX-M- VEB- 0143-8540 - - Department of Microbiology and Infectious Diseases, Toho University Faculty of Medicine (5-21-16 Omori-nishi, Ota-ku, Tokyo)
mbler mbler 1 C 2 2a 2b 2be 2br 2c 2d 2e 2f, D D TEM-1 TEM-2 SHV-1 TEM- IRT SHV-10 SHV-49 3 3a, 3b, 3c B - GES- ESBL Hahey Clinic Jacoby Bush mino cid Sequences for TEM, SHV and OX Extended-Spectrum and Inhibitor Resistant β-lactamases http: www.lahey.org Studies TEM- SHV- CTX- M- VEB- GES- PER- 126 90 59 3 9 3 2006 7 12 C C C ESBL Clinical Laboratory and Standards Institute CLSI NCCLS 4 CLSI ESBL Klebsiella oxytoca Proteus mirabilis 4 ESBL SENTRY ESBL 1998 2002 ESBL 35.6 30.7 21.9 ESBL 24.5 14.3 11.3 ESBL P. mirabilis 17.9 8.1 ESBL P. mirabilis ESBL 10 2.4 3.7 5
Klebsiella oxytoca Proteus mirabilis ESBL Mueller-Hinton Klebsiella oxytoca 10µg 30µg 30µg 30µg 30µg 10µg 30µg 30µg Klebsiella oxytoca 17mm 22mm 27mm 27mm 25mm 22mm 22mm 27mm Klebsiella pneumoniae TCC 700603 9-16mm 10-18mm 9-17mm 17-25mm 16-24mm Mueller-Hinton 30µg 30 10µg 30µg 30 10µg 5mm 5mm 3mm 3 3 2 1 2005 P. mirabilis ESBL 0.16 0.4 0.16 SENTRY ESBL TEM- SHV- CTX-M- ESBL 6 ESBL FEC-1 DN ESBL Toho-1 7 DN CTX-M-
Klebsiella oxytoca Proteus mirabilis ESBL Mueller-Hinton Klebsiella oxytoca 4µg ml 1µg ml 1µg ml 1µg ml 1µg ml 1µg ml 1µg ml 1µg ml 0.25-128µg ml 0.25 4-128 4µg ml 0.25-64µg ml 0.25 4-64 4µg ml Klebsiella oxytoca 8µg ml 2µg ml 2µg ml 2µg ml 2µg ml 2µg ml 2µg ml 2µg ml Klebsiella pneumoniae TCC 700603 8µg ml 2µg ml 2µg ml 2µg ml 2µg ml MIC 3 MIC MIC 3 MIC 3 ESBL 8 CTX-M- 59 DN CTX-M- 9 TEM- SHV- CTX-M- ESBL CTX-M- ESBL 6 ESBL CTX-M- CTX-M-
Mendelson ESBL 3 ESBL 10 ESBL 11 CLSI ESBL KB 4 ESBL CTX-M- CLSI Enterobacter spp. Citrobacter spp. Serratia spp. ESBL C C ESBL I CV 12 Etest ESBL ESBL DN ESBL 1 ESBL TEM- SHV- ESBL CTX-M- ESBL TEM- SHV- ESBL CTX-M- ESBL ESBL 13 ESBL 14 CLSI ESBL ESBL
ESBL ESBL PCR ESBL ESBL CTX-M- ESBL CTX-M- ESBL ESBL D ESBL 1 Knothe H, Shah P, Krcmery V, ntal M, Mitsuhashi S.: Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens. Infection, 6 : 315-317, 1983. 2 mbler RP.: The structure of β-lactamases. Philosophical transactions of the Royal Society of London, 1036 : 321-331, 1980. 3 Bush K.: New β-lactamases in gram-negative bacteria : diversity and impact on the selection of antimicrobial therapy. Clin Infect Dis, 7 : 1085-1089, 2001. 4 Clinical and Laboratory Standards Institute : Performance Standards for ntimicrobial Susceptibility Testing ; Sixteenth Informational Supplement. M100-S16. Wayne, Pa.: Clinical and Laboratory Standards Institute ; 2006. 5 Hirakata Y, Matsuda J, Miyazaki Y, Kamihira S, Kawakami S, Miyazawa Y, Ono Y, Nakazaki N, Hirata Y, Inoue M et al.: Regional variation in the prevalence of extendedspectrum β-lactamase-producing clinical isolates in the sia-pacific region SENTRY 1998-2002. Diagnostic Microbiology and Infectious Disease, 4 : 323-329, 2005. 6 Canton R, Coque TM.: The CTX-M β-lactamase pandemic. Current Opinion in Microbiology, 5 : 466-475, 2006. 7 Ishii Y, Ohno, Taguchi H, Imajo S, Ishiguro M, Matsuzawa H.: Cloning and sequence of the gene encoding a cefotaxime-hydrolyzing class β-lactamase isolated from Escherichia coli. ntimicrobial gents and Chemotherapy, 10 : 2269-2275, 1995.
8 Ibuka, Taguchi, Ishiguro M, Fushinobu S, Ishii Y, Kamitori S, Okuyama K, Yamaguchi K, Konno M, Matsuzawa H.: Crystal structure of the E166 mutant of extended-spectrum β-lactamase Toho-1 at 1.8 resolution. Journal of Molecular Biology, 5 : 2079-2087, 1999. 9 Kojima, Ishii Y, Ishihara K, Esaki H, sai T, Oda C, Tamura Y, Takahashi T, Yamaguchi K.: Extended-spectrum-β-lactamase-producing Escherichia coli strains isolated from farm animals from 1999 to 2002 : report from the Japanese Veterinary ntimicrobial Resistance Monitoring Program. ntimicrobial gents and Chemotherapy, 8 : 3533-3537, 2005. 10 Mendelson G, Hait V, Ben-Israel J, Gronich D, Granot E, Raz R.: Prevalence and risk factors of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae in an Israeli long-term care facility. Eur J Clin Microbiol Infect Dis, 1 : 17-22, 2005. 11 Paterson DL, Bonomo R.: Extended-spectrum β-lactamases : a clinical update. Clinical Microbiology Reviews, 4 : 657-686, 2005. 12 Hanaki H, Yamazaki H, Harada H, Kubo R, Kobayashi T, tsuda K, Sunakawa K.: The synthesis of 7-substituted-3- dinitrostyryl cephalosporins and their ability for detecting extended spectrum β-lactamases ESBLs. The Journal of ntibiotics, 1 : 69-73, 2005. 13 Ishii Y, Galleni M, Ma L, Frere JM, Yamaguchi K.: Biochemical characterisation of the CTX-M-14 β-lactamase. International Journal of ntimicrobial gents, 2 : 159-164, 2007. 14 Paterson DL, Ko WC, Von Gottberg, Casellas JM, Mulazimoglu L, Klugman KP, Bonomo R, Rice LB, McCormack JG, Yu VL.: Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum β-lactamases : implications for the clinical microbiology laboratory. Journal of Clinical Microbiology, 6 : 2206-2212, 2001.